

## Decreased PM<sub>10</sub> Exposure Attenuates Age-Related Lung Function Decline: Genetic Variants in *p53*, *p21*, and *CCND1* Modify This Effect

Medea Imboden,<sup>1,2</sup> Joel Schwartz,<sup>3</sup> Christian Schindler,<sup>4</sup> Ivan Curjuric,<sup>1,4</sup> Wolfgang Berger,<sup>2</sup> Sally L.J. Liu,<sup>4</sup> Erich W. Russi,<sup>5</sup> Ursula Ackermann-Lieblich,<sup>4</sup> Thierry Rochat,<sup>6</sup> Nicole M. Probst-Hensch,<sup>1</sup> and the SAPALDIA Team

<sup>1</sup>Department of Chronic Disease Epidemiology, Institute of Social and Preventive Medicine, and <sup>2</sup>Institute of Medical Genetics, University of Zurich, Zurich, Switzerland; <sup>3</sup>Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; <sup>4</sup>Institute of Social and Preventive Medicine, University of Basel, Basel, Switzerland; <sup>5</sup>Department of Pneumology, University Hospital Zurich, Zurich, Switzerland; <sup>6</sup>Division of Pulmonary Medicine, University Hospitals Geneva, Geneva, Switzerland

**BACKGROUND:** Decreasing exposure to airborne particulates was previously associated with reduced age-related decline in lung function. However, whether the benefit from improved air quality depends on genetic background is not known. Recent evidence points to the involvement of the genes *p53* and *p21* and of the cell cycle control gene cyclin D1 (*CCND1*) in the response of bronchial cells to air pollution.

**OBJECTIVE:** We determined in 4,326 participants of the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) whether four single-nucleotide polymorphisms in three genes [*CCND1* (rs9344 [P242P], rs667515), *p53* (rs1042522 [R72P]), and *p21* (rs1801270 [S31R])] modified the previously observed attenuation of the decline in the forced expiratory flow between 25% and 75% of the forced vital capacity (FEF<sub>25–75</sub>) associated with improved air quality.

**METHODS:** Subjects of the prospective population-based SAPALDIA cohort were assessed in 1991 and 2002 by spirometry, questionnaires, and biological sample collection for genotyping. We assigned spatially resolved concentrations of particulate matter with aerodynamic diameter  $\leq 10 \mu\text{m}$  (PM<sub>10</sub>) to each participant's residential history 12 months before the baseline and follow-up assessments.

**RESULTS:** The effect of diminishing PM<sub>10</sub> exposure on FEF<sub>25–75</sub> decline appeared to be modified by *p53* R72P, *CCND1* P242P, and *CCND1* rs667515. For example, a 10- $\mu\text{g}/\text{m}^3$  decline in average PM<sub>10</sub> exposure over an 11-year period attenuated the average annual decline in FEF<sub>25–75</sub> by 21.33 mL/year (95% confidence interval, 10.57–32.08) among participants homozygous for the *CCND1* (P242P) GG genotype, by 13.72 mL/year (5.38–22.06) among GA genotypes, and by 6.00 mL/year (–4.54 to 16.54) among AA genotypes.

**CONCLUSIONS:** Our results suggest that cell cycle control genes may modify the degree to which improved air quality may benefit respiratory function in adults.

**KEY WORDS:** air pollution, cell cycle, cohort study, genes, respiratory function tests. *Environ Health Perspect* 117:1420–1427 (2009). doi:10.1289/ehp.0800430 available via <http://dx.doi.org/> [Online 26 May 2009]

A large body of evidence underscores the adverse effect of long-term exposure to ambient particulate matter (PM) air pollution on respiratory health (Brunekreef and Forsberg 2005; Gotschi et al. 2008). Among adults in Switzerland, we have previously demonstrated cross-sectionally that residents of more polluted areas have lower lung function (Ackermann-Lieblich et al. 1997). More recently, we presented evidence from the same population-based cohort [Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA)] that decreasing exposure to airborne PM attenuated the average age-related decline in lung function. The associations were strongest for respiratory function tests reflecting small-airway function, namely, FEF<sub>25–75</sub> [forced expiratory flow between 25% and 75% of forced vital capacity (FVC)] (Downs et al. 2007). Similar results from studies following interventions such as building bypasses for congested traffic routes (Burr et al. 2004; Hedley et al. 2002) or banning environmental tobacco smoke (ETS) exposure (Goodman et al. 2007; Menzies et al. 2006) showed that

the improvements in air quality were accompanied by a decrease in cardiopulmonary mortality and an improvement in respiratory symptoms and lung function. However, it is still unknown whether all subjects benefit equally from a reduction in air pollution.

Variation in genes mediating the pathological effect of air pollution in the lung may codetermine the degree to which a person benefits from better air quality. Experimental evidence indicates that PM alters expression of tumor protein gene *p53*, cyclin-dependent kinase inhibitor 1A gene (*p21*), and the cyclin D1 gene (*CCND1*) and subsequently affects cell proliferation and apoptosis of lung fibroblasts, lymphocytes, and alveolar epithelial cells (Bayram et al. 2006; Dagher et al. 2006; Nyunoya et al. 2006; Rosas Perez et al. 2007; Soberanes et al. 2006). PM is furthermore well known to induce oxidative stress in the airways (Li et al. 2008). In fact, the expression of all three gene candidates, *p53*, *p21*, and *CCND1*, in bronchial epithelial cells and lung fibroblasts seems to be regulated in part by redox-dependent mechanisms (Jiao et al. 2008; Ranjan et al. 2006; Yao et al. 2008).

The tumor suppressor *p53*, a nuclear transcription factor, binds to response elements in the promoter region of many genes and plays a pivotal role in apoptosis. It induces up-regulation of the expression of many pro-apoptotic genes and down-regulation of anti-apoptotic genes (Oren et al. 2002). *CCND1* (cyclin D1) is known to promote cell proliferation through cell cycle G1–S phase transition. The protein *p21* (also known as *Waf1* or *Cip1*) is a direct functional counterpart of *CCND1* and an important downstream effector of *p53* action that negatively regulates cell proliferation. *CCND1*, *p21*, and *p53* all harbor polymorphisms of hypothesized functional relevance that have been extensively studied in the context of cancer (Choi et al. 2008; Lu et al. 2008; Zhou et al. 2007). In this study, we examined whether these polymorphisms modified the degree to which the

Address correspondence to N.M. Probst-Hensch, Department of Chronic Disease Epidemiology, Institute of Social and Preventive Medicine, Sumatrastrasse 30, CH-8006 Zurich, Switzerland. Telephone: 41-44-634-53-73. Fax: 41-44-634-40-09. E-mail: Nicole.Probst@ifspm.uzh.ch

Supplemental Material is available online (doi:10.1289/ehp.0800430.S1 via <http://dx.doi.org/>)

The study could not have been done without the help of the study participants, technical and administrative support, and the medical teams and fieldworkers at the local study sites: local field-workers M. Broglie, M. Bünter, D. Gashi (Aarau); R. Armbruster, T. Damm, U. Egermann, M. Gut, L. Maier, A. Vögelin, L. Walter (Basel); D. Jud, N. Lutz (Davos); M. Ares, M. Bennour, B. Galobardes, E. Namer (Geneva); B. Baumberger, S. Boccia Soldati, E. Gehrig-Van Essen, S. Ronchetto (Lugano); C. Bonvin, C. Burrus (Montana); S. Blanc, A.V. Ebinger, M.L. Fragnière, J. Jordan (Payerne); and R. Gimmi, N. Kourkoulos, U. Schafroth (Wald); and administrative staff N. Bauer, D. Baehler, C. Gabriel, and R. Nilly.

Research support was provided by the Swiss National Science Foundation (grants 4026-28099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, and 32-4253.94); Swiss Federal Office for Forest, Environment, and Landscape; Swiss Federal Office of Public Health; Swiss Federal Office of Roads and Transport; canton governments of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, and Zurich; Swiss Lung League; canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino, and Zurich; and the Walter-Honegger Foundation.

The authors declare they have no competing financial interests.

Received 27 November 2008; accepted 26 May 2009.

age-related FEF<sub>25-75</sub> decline was attenuated by reduced exposure to PM with aerodynamic diameter  $\leq 10 \mu\text{m}$  (PM<sub>10</sub>).

## Materials and Methods

**SAPALDIA cohort study population.** The study design and methodology of SAPALDIA have been described in detail elsewhere (Ackermann-Lieblich et al. 2005; Martin et al. 1997). In 1991, health examinations focusing on respiratory health status were conducted in 9,651 adults (18–60 years of age) randomly selected from population registries of eight environmentally diverse areas of Switzerland. Ethical approval was obtained from the Swiss Academy of Medical Sciences and the Regional Ethics Committees. Written informed consent was obtained from all participants before health examination and biological sample collection at both surveys. Nonparticipation at follow-up and missing information on covariates led to the exclusion of participants for the present study [see Supplemental Material, Figure 1 and Table 2 available online (doi:10.1289/ehp.0800430.S1 via <http://dx.doi.org>)]. In summary, of the 9,651 subjects who initially participated at baseline (SAPALDIA1), 1,604 had died, left Switzerland, or refused to participate at the follow-up examination (SAPALDIA2). Of 8,047 cohort participants remaining, 5,732 completed the interview questionnaire and spirometry at both the baseline and follow-up surveys. Participants were excluded from the analysis ( $n = 1,406$ ) if they had lived for  $< 1$  year at their last residential address at follow-up, could not be assigned home outdoor PM<sub>10</sub> concentrations, or did not provide blood samples for DNA extraction or if the genetic analysis of their sample was unsuccessful. Thus, the present study sample included 4,326 participants with available blood samples and genotype data and complete data from both surveys on spirometry, smoking history, PM<sub>10</sub> exposure, and residential history during follow-up.

**Lung function assessment.** Identical spirometer devices (model 2200, SensorMedics Corp., Yorba Linda, CA, USA) and protocols were used at baseline and follow-up examinations, and their comparability was assessed before the follow-up study (Künzli et al. 1995, 2005). Details of these measurements have been described elsewhere (Ackermann-Lieblich et al. 2005; Downs et al. 2005). Briefly, three to eight forced expiratory lung function maneuvers were performed by each participant to obtain a minimum of two measures of FEF, FVC, forced expiratory volume in the first second (FEV<sub>1</sub>), and FEF<sub>25-75</sub> that were considered acceptable according to American Thoracic Society (1995) criteria. Expiratory flow measures were taken from the same flow-volume curve. For each participant, the rate

of change in lung function was defined as the difference in each parameter between the two examinations (measurement at follow-up minus measurement at baseline), divided by the participant-specific follow-up time (in nontruncated years).

**Selection of genetic variants.** We selected the same common, well-studied, and potentially functional candidate single-nucleotide polymorphism (SNP) in *CCND1* [proline-to-proline substitution at amino acid 242 (P242P), rs9344] that we evaluated in our previous research on the interaction of *CCND1* with oxidative stress in breast and colon cancer (Ceschi et al. 2005; Probst-Hensch et al. 2006). We selected one additional common SNP in the *CCND1* gene (rs667515) based on a pilot study involving haplotype-tagging polymorphisms in *CCND1* and their association with accelerated lung function decline in a subsample of the SAPALDIA cohort (unpublished observations). In addition, we examined SNPs in two other important cell cycle control genes that have been repeatedly assessed in cancer association studies and are reported to have a functional effect: *p53* [arginine-to-proline substitution at amino acid 72 (R72P), rs1042522] (Bergamaschi et al. 2006) and *p21* [serine-to-arginine substitution at amino acid 31 (S31R), rs1801270] (Lukas et al. 1997).

**Genotyping.** DNA was extracted from EDTA-buffered whole blood as previously described (Ackermann-Lieblich et al. 2005). Genotyping strategy used was fluorescent 5'-nuclease real-time polymerase chain reaction (TaqMan, Applied Biosystems, Rotkreuz, Switzerland) methodology using ABI Prism 7900 sequence detection system (ABI, Rotkreuz, Switzerland). The SNP-specific primers and locked nucleic acid (LNA) dual-labeled fluorogenic probes were designed by Sigma Prologis (Evry, France). SNP-specific probes and primers were as follows: rs1042522, 5'-CTGCTCCCC[C/G]CGTGGC-3', forward 5'-ACTGAAGACCCAGGTCCA-3', reverse 5'-GCCGGTGTAGGAGCT-3'; rs1801270, 5'-GCTGAG[C/A]CGCGAC-3', forward 5'-TGCCGCCGCTCTT-3', reverse 5'-GATGCAGCCCGCCATTAG-3'; rs667515, 5'-AGCTCCCTTGC[G/C]CCC-3', forward 5'-TGGCTTCATCAGATGACAAAC-3', reverse 5'-AACCTGGGCTTCTCCAA-3'; rs9344, 5'-TGTGACCC[A/G]GTAAGTGA-3', forward 5'-ACGCTTCTCTCCAGAG-3', reverse 5'-CAAGGCTGCCTGG-3'. A 10% random sample of all DNA samples was genotyped, and all genotypes were confirmed. The genotype call rate was  $> 99\%$ .

**Individual residential PM<sub>10</sub> exposure assessment.** Air pollution exposure assessment has been described in detail elsewhere (Downs et al. 2007; Liu et al. 2007). We estimated PM<sub>10</sub> exposure for each participant according

to residential history using a hybrid exposure model incorporating Gaussian dispersion (from PolluMap model, version 2.0; Liu et al. 2007) and geoinformation based on data on seasonal, meteorologic, and geographic annual emission characteristics from various source categories (e.g., traffic, industrial, regional, and agricultural activities) (Liu et al. 2007). Hourly concentrations of PM<sub>10</sub> were simulated with a spatial resolution of  $200 \times 200$  m grid cells for 1990 and 2002. Annual average PM<sub>10</sub> exposure concentrations during follow-up were estimated for each residential address with the help of an algorithm that allowed interpolation of modeled values on the basis of historical trends in central-site measurements between 1990 and 2002. Evaluation of dispersion model predictions using a total of 57 PM<sub>10</sub> Swiss central-site monitors has been described elsewhere (Liu et al. 2007). Based on the validated dispersion model, each subject was assigned an annual PM<sub>10</sub> concentration every year between 1990 and 2002. For that purpose, modeled PM<sub>10</sub> concentrations were averaged over the year to obtain annual averages for each grid cell. Each participant's residential history was coded using the geographic information system data. Assignment of individual PM<sub>10</sub> exposure was performed by matching address codes with annual concentrations derived from the grid cells generated by the dispersion model.

The exposure variable used for the present study was the difference in the annual average PM<sub>10</sub> exposure between 2002 and 1991. It was calculated for each participant as follows: average home outdoor PM<sub>10</sub> concentration in the 12 months before the baseline examination was subtracted from the corresponding average concentration in the 12 months before the follow-up examination, and this difference was divided by the mean time of follow-up (in nontruncated years). In our previous study (Downs et al. 2007), we used two exposure indexes: *a*) the difference in the annual average exposure between 2002 and 1991 (the index used in the present study) and *b*) the "interval exposure," defined as the sum of the annual exposures for each subject for each year of follow-up between their examinations. Because of the high correlation ( $R^2 > 0.9$ ) between these two exposure variables, we were unable to single out the superior measure in our previous report. Both indices showed similar associations with change in lung function (Downs et al. 2007).

**Collection of data on covariates.** Information on relevant covariates known or likely to determine lung function decline, such as age, height, smoking history, ETS exposure, occupational exposure, and education level, was gathered in a computer-assisted, individually administered interview based on the European Community Respiratory Health Survey questionnaire (Burney et al. 1994).

Current and past smoking habits, exposure to ETS, and occupational exposure to dust and fumes were assessed with the same questions at both surveys. Participants who reported smoking < 20 packs of cigarettes and using < 360 g of tobacco in their lifetime at both time points were defined as never-smokers. Cumulative cigarette exposure of participants was assessed by pack-years smoked before the first examination and pack-years smoked during follow-up. Participants were asked not to smoke in the hour before the examination, and smoking was validated by measuring the carbon monoxide concentration in exhaled breath using an EC 50 Micro-Smokerlizer (Bedfont Scientific, Rochester, UK). Atopic status was assessed at baseline using skin prick tests (Phazet; Pharmacia, Uppsala, Sweden) for eight common inhalant allergens: dog epithelium; cat fur; pollen of timothy grass, *Parietaria*, and birch; the house dust mite *Dermatophagoides pteronyssinus*; and the molds *Alternaria tenuis* and *Cladosporium herbarum* (Martin et al. 1997; Wuthrich et al. 1996). Atopy was defined by an adjusted mean wheal diameter  $\geq 3$  mm to at least one allergen.

**Statistical analysis.** We inferred *CCND1* haplotypes from unphased genotype data using PHASE 2.1 algorithm software [see Supplemental Material, Table 1 (doi:10.1289/ehp.0800430.S1)] (Stephens et al. 2001). Hardy-Weinberg equilibrium was tested using STATA gtab command for global  $\chi^2$ -statistic testing (STATA version 10; StataCorp, College Station, TX, USA). All four SNPs were in Hardy-Weinberg equilibrium. We obtained Lewtonin's linkage disequilibrium (LD) metric  $D'$  using STATA command pwld for pairwise LD. Descriptive analyses of the lung function parameters,  $PM_{10}$ , smoking, socioeconomic variables, and other relevant covariates have been described previously and in detail in different SAPALDIA cohort study reports (Ackermann-Lieblich et al. 2005; Downs et al. 2007; Imboden et al. 2007). We compared baseline characteristics of the cohort participants included in this study ( $n = 4,326$ ) with subjects participating only at baseline as well as with cohort participants excluded from this analysis because information on genotype or covariate data was missing.

Results are presented as the estimated effect of a  $10\text{-}\mu\text{g}/\text{m}^3$  decrease in the annual average  $PM_{10}$  exposure over the follow-up period ( $\Delta PM_{10}$ ) on the average attenuation of the annual decline in  $FEF_{25-75}$ .

The association between  $\Delta PM_{10}$  and the average annual rate of lung function decline had been previously assessed using mixed linear model analysis, and selection of relevant covariates was based on this previous investigation (Downs et al. 2007): age at baseline (SAPALDIA1), age<sup>2</sup>, sex, height, parental smoking during childhood reported

at baseline, sine and cosine function of day of examination to control for seasonal effects, level of education at baseline, change in level of education, Swiss nationality, self-reported occupational exposure to dust and occupational exposure to fumes at SAPALDIA1 and SAPALDIA2 (yes/no), smoking status at follow-up (never, former, or current), pack-years up to SAPALDIA1, pack-years between SAPALDIA1 and -2, cigarettes per day at SAPALDIA1 and -2, atopy, body mass index (BMI) at SAPALDIA1, change in BMI, interaction between the two BMI variables, and baseline  $PM_{10}$  exposure. Random effects were included to adjust for clustering of residuals within area and were assumed to be independent between the areas and to have an exchangeable correlation structure. To estimate main effects of gene variants of *CCND1*, *p21*, and *p53* and rate of lung function decline, we used the same mixed model with random area effects additionally adjusted for  $\Delta PM_{10}$ . To estimate modification of the  $\Delta PM_{10}$  effect on average lung function decline by genotype, we introduced interaction terms between  $\Delta PM_{10}$  and genotypes into the above-described covariate-adjusted mixed linear models independently for each SNP. Also, for each SNP we evaluated three different genetic models (codominant, dominant, and recessive) because previous cancer association studies were not conclusive about the underlying genetic model of the SNP effects. The codominant model assumes that the gene effect depends on the number of alleles in a dose-dependent manner, the dominant model assumes that the gene effect depends on the presence of at least one of two high-risk alleles, and the recessive model assumes that the gene effect depends on the presence of both high-risk alleles. The three genetic models required different coding of genotypes. For each SNP we present the genetic model with the smallest interaction term  $p$ -value. We obtained effect estimates for the association between  $\Delta PM_{10}$  and average annual lung function decline in genotype subgroups by creating genotype-specific  $PM_{10}$  exposures variables that we introduced into separate covariate-adjusted mixed linear models. Analyses were conducted using SAS release 9.1 (SAS Institute Inc., Cary, NC, USA) and STATA version 10.  $p$ -Values < 0.05 were interpreted as statistically significant for main and interaction effects.  $p$ -Values presented as main  $p$ -values in the tables are not corrected for multiple testing. Nevertheless, Bonferroni-corrected significance level ( $\alpha = 0.05$  divided by the number of tests) is indicated in tables and figures as appropriate.

## Results

**Population characterization.** Table 1 describes the general characteristics of the study population ( $n = 4,326$ ), including relevant predictors

of lung function. This is a population consisting mostly of Caucasians. At follow-up participants were more likely to be women and less likely to be smokers than were non-participants. Participants tended to gain weight, give up smoking, and reduce exposure to dust or fumes at work or to ETS [for details, see Supplemental Material, Table 2 (doi:10.1289/ehp.0800430.S1)].

In 2002, 87% of the participants were living in the same area as in 1991, and 54% had the same address. In general, individual home outdoor concentrations of  $PM_{10}$  declined during the follow-up period (Table 1), as previously described in detail (Downs et al. 2007; Liu et al. 2007). The median decline between examinations for subjects included in this analysis was  $5.8\ \mu\text{g}/\text{m}^3$  (interquartile range,  $4.2\text{--}7.3\ \mu\text{g}/\text{m}^3$ ). Mean decline was greatest for participants living in urban areas and lowest in alpine areas.

Mean lung function for the cohort was within the range of predicted values for the general population and declined during the follow-up period (Table 1). The mean  $\pm$  SD annual change in mid  $FEF_{25-75}$  during the 11-year follow-up period was  $-74.1 \pm 70.3$  mL/year in men and  $-68.9 \pm 58.9$  mL/year in women included in this analysis.

The main effects of the investigated genetic variants on change in lung function are described in more detail in Supplemental Material, Table 3 (doi:10.1289/ehp.0800430.S1). Briefly, we observed no statistically significant associations of the polymorphisms either with change in  $FEF_{25-75}$  or with  $FEV_1$  or FVC.

**Modification of the  $\Delta PM_{10}$  effect on average decline in lung function by genotype.** As previously reported (Downs et al. 2007), a  $10\text{-}\mu\text{g}/\text{m}^3$  decline in average annual home outdoor  $PM_{10}$  concentration over an 11-year period ( $\Delta PM_{10}$ ) reduced the annual rate of decline in  $FEF_{25-75}$  on average by 11.2 mL/year or 16%. Here we report statistically significant modifications of this association of  $\Delta PM_{10}$  with  $FEF_{25-75}$  decline by three of the four genetic variants investigated: *CCND1* P242P [ $p$ -value for interaction ( $p_{\text{int}} = 0.017$ )], *CCND1* rs667515 ( $p_{\text{int}} = 0.006$ ), and *p53* R72P ( $p_{\text{int}} = 0.016$ ). Figure 1A and Table 2 present results for the association of  $\Delta PM_{10}$  with the average annual change in  $FEF_{25-75}$  within genotype and diplotype strata for the entire study population; for data for never-smokers, see Figure 1B and Supplemental Material, Table 4 (doi:10.1289/ehp.0800430.S1). Equivalent to the previously reported main effect of  $\Delta PM_{10}$  (Downs et al. 2007), the genotype-specific results we observed in the entire study population were comparable to those in never-smokers. The A allele for *CCND1* P242P reduced the attenuating effect estimate of  $\Delta PM_{10}$  on  $FEF_{25-75}$  decline in a codominant



manner. A 10 µg/m<sup>3</sup> decline in PM<sub>10</sub> over an 11-year period was associated with an average attenuation of annual decline in FEF<sub>25-75</sub> of 6.0 mL/year [95% confidence interval (CI), -4.54 to 16.54] in participants with an AA genotype, 13.7 mL/year (5.38–22.06) in heterozygous AG participants, and 21.3 mL/year (10.57–32.08) in participants with a GG genotype.

For the *CCND1* rs667515 SNP, the beneficial ΔPM<sub>10</sub> effect was most pronounced in participants homozygous for the minor allele (CC genotype) and attenuated annual FEF<sub>25-75</sub> decline in this subgroup by 28.83 mL/year (95% CI, 15.60–42.07) compared with 10.39 (3.24–20.47) and 11.83 (1.32–19.47) among GG and GC genotypes, respectively. This effect modification thus followed a recessive genetic model.

For the *p53* R72P SNP, the observed effect modification followed a codominant model. ΔPM<sub>10</sub> was associated with an average attenuation of annual FEF<sub>25-75</sub> decline by an average of 17.4 mL/year (95% CI, 8.95–25.78) in GG genotypes (Pro/Pro) and by an average of 11.6 mL/year (2.65–20.61) in CG genotypes (Arg/Pro) but no attenuation in CC genotypes (Arg/Arg).

*CCND1* haplotypes 2 and 3, but not 1 and 4, were also statistically significant modifiers of the ΔPM<sub>10</sub> association with FEF<sub>25-75</sub> decline. In participants exhibiting the *CCND1* haplotype 3 (CG/CG) on both alleles (representing the combination of the single SNP alleles associated with the greatest lung function attenuation), the effect estimate for attenuation of FEF<sub>25-75</sub> decline associated

with ΔPM<sub>10</sub> was 30.9 mL/year (95% CI, 17.21–44.58) compared with 11.92 (3.40–20.44) and 10.28 (1.22–19.35) among subjects with the CG haplotype in one or none of their alleles (Table 2).


Genotype-specific ΔPM<sub>10</sub> effect estimates for the attenuation of the average annual decline in FEV<sub>1</sub> and FVC are presented in Supplemental Material, Table 5 (doi:10.1289/ehp.0800430.S1). For FEV<sub>1</sub> decline, effect modification by genotypes was comparable to that seen for FEF<sub>25-75</sub> decline. Again, effect modification was strongest for the *CCND1* rs667515 SNP and for *CCND1* haplotype 3 [see Supplemental Material, Table 5 (doi:10.1289/ehp.0800430.S1)] We observed no modification of the ΔPM<sub>10</sub> effect on FVC decline for any of the SNPs or haplotypes.

**Table 1.** Characteristics of the study population: SAPALDIA cohort.

Characteristic	Participants (n = 4,326)	Characteristic	Participants (n = 4,326)
Female (%)	53.0	Annual change [mean ± SD] (mL/year) <sup>b</sup>	
Swiss nationality (%)	87.7	FVC in women	-20.79 ± 34.11
Educational level in 2002 (professional education or higher, %)	27.9	FVC in men	-29.17 ± 45.47
Increase in educational level between surveys (%)	17.9	FEV <sub>1</sub> in women	-31.88 ± 25.72
Age in 1991 [mean ± SD (years)]	41.3 ± 11.2	FEV <sub>1</sub> in men	-39.77 ± 32.91
Height [mean ± SD (cm)]	169.3 ± 8.8	FEF <sub>25-75</sub> in women	-68.89 ± 58.88
BMI in 1991 [mean ± SD (kg/m <sup>2</sup> )]	23.7 ± 3.6	FEF <sub>25-75</sub> in men	-74.11 ± 70.24
BMI change [mean ± SD (kg/m <sup>2</sup> )]	2.1 ± 2.2	Genotype distribution	
Smoking		<i>p53</i> P72R, rs1042522	
Never-smokers in 1991 (%)	48.4	GG	2,407
Never-smokers in 2002 (%)	49.3	CG	1,637
Smoking quitters during follow-up (%)	8.1	CC	282
Current smokers in 1991 (%)	29.3	<i>p21</i> S31R, rs1801270	
Current smokers in 2002 (%)	21.9	CC	3,701
No. of pack-years for current smokers in 2002 [median (IQR)]	26.7 (14.0–42.6)	CA or AA <sup>c</sup>	625
Cigarettes per day for current smokers in 1991 [median (IQR)]	20 (10–25)	<i>CCND1</i> P242P, rs9344	
Cigarettes per day for current smokers in 2002 [median (IQR)]	15 (7–20)	GG	1,211
Passive smoking and occupational exposure (%)		GA	2,140
ETS exposure in never-smokers in 1991	13.1	AA	975
ETS exposure in never-smokers in 2002	7.7	<i>CCND1</i> -7006G>C, rs667515	
Father or mother smoked during childhood	56.1	GG	1,628
Workplace exposure to dust and fumes in 1991	30.3	GC	2,058
Workplace exposure to dust and fumes in 2002	13.2	CC	640
Atopy in 1991	22.3	Diplotype distribution <sup>d</sup>	
Change in average individual home outdoor PM <sub>10</sub> exposure <sup>a</sup>		<i>CCND1</i> haplotype 1 (rs667515, rs9344)	
All areas (n = 4,326)	-5.8 (-7.3 to -4.2)	-/-	3,125
Basel area (n = 486)	-8.0 (-9.1 to -6.9)	GG/-	1,088
Wald area (n = 889)	-4.5 (-4.8 to -3.9)	GG/GG	113
Davos area (n = 318)	-3.0 (-3.1 to -2.8)	<i>CCND1</i> haplotype 2 (rs667515, rs9344)	
Lugano area (n = 568)	-12.1 (-13.5 to -10.8)	-/-	1,251
Montana area (n = 431)	-4.0 (-4.2 to -3.7)	GA/-	2,150
Payerne area (n = 595)	-5.0 (-5.3 to -4.6)	GA/GA	925
Aarau area (n = 689)	-6.4 (-6.8 to -5.8)	<i>CCND1</i> haplotype 3 (rs667515, rs9344)	
Geneva area (n = 350)	-6.2 (-7.3 to -5.7)	-/-	1,678
Lung function in 1991 [mean ± SD (L)] <sup>b</sup>		CG/-	2,048
FVC in women	3.82 ± 0.61	CG/CG	600
FVC in men	5.30 ± 0.82	<i>CCND1</i> haplotype 4 (rs667515, rs9344)	
FEV <sub>1</sub> in women	3.07 ± 0.55	-/-	4,239
FEV <sub>1</sub> in men	4.11 ± 0.72	CA/-	84
FEF <sub>25-75</sub> in women	3.07 ± 1.00	CA/CA	3
FEF <sub>25-75</sub> in men	3.79 ± 1.29		

IQR, interquartile range.

<sup>a</sup>PM<sub>10</sub> (µg/m<sup>3</sup>) in the year before SAPALDIA1 minus PM<sub>10</sub> in the year before SAPALDIA2. <sup>b</sup>Women, n = 2,293; men, n = 2,033. <sup>c</sup>Genotype distribution: *p21* CA, n = 594; *p21* AA, n = 31. <sup>d</sup>Diplotype distribution is labeled as follows: -/-, none of the specific haplotypes present; (rs667515, rs9344)/- (e.g., GG/-), one of the specific haplotypes present; (rs667515, rs9344)/(rs667515, rs9344) (e.g., GG/GG), for two of the specific haplotypes present.



**Figure 1.** Attenuation of average annual FEF<sub>25-75</sub> decline associated with a 10-µg/m<sup>3</sup> decrease in average home outdoor PM<sub>10</sub> exposure between 1991 and 2002, by genotype status, in all study participants (A) and in never-smokers only (B). A positive value for FEF<sub>25-75</sub> on the y-axis represents the average attenuation in lung function decline associated with an average 10-µg/m<sup>3</sup> PM<sub>10</sub> decrease during follow-up period. Bonferroni significance level for four comparisons  $p = 0.013$ .

**Table 2.** Effect modification by genotypes: association<sup>a</sup> of change in average home outdoor PM<sub>10</sub> (per decrease of 10 µg/m<sup>3</sup> between 1991 and 2002) with average annual decline in FEF<sub>25-75</sub> (mL/year), by genotype status.

Genotype	No.	Average annual FEF <sub>25-75</sub> decline <sup>b</sup>	95% CI	p-Value	p <sub>int</sub> <sup>c</sup>
<i>p53</i> R72P; rs1042522					
GG	2,407	17.37	8.95 to 25.78	< 0.001	0.016 <sub>(codominant)</sub>
CG	1,637	11.63	2.65 to 20.61	0.011	
CC	282	-4.33	-21.37 to 12.7	0.618	
<i>p21</i> S31R; rs1801270					
CC	3,701	12.72	5.35 to 20.1	0.001	0.115 <sub>(dominant)</sub>
CA or AA <sup>d</sup>	625	23.88	9.25 to 38.51	0.001	
<i>CCND1</i> P242P; rs9344					
GG	1,211	21.33	10.57 to 32.08	< 0.001	0.017 <sub>(codominant)</sub>
AG	2,140	13.72	5.38 to 22.06	0.001	
AA	975	6.00	-4.54 to 16.54	0.265	
<i>CCND1</i> -7006G>C; rs667515					
GG	1,628	10.39	1.32 to 19.47	0.025	0.006 <sub>(recessive)</sub>
CG	2,058	11.83	3.24 to 20.42	0.007	
CC	640	28.83	15.6 to 42.07	< 0.001	
<i>CCND1</i> haplotype 1 (rs667515, rs9344) <sup>e</sup>					
-/-	3,125	13.67	5.99 to 21.34	< 0.001	0.156 <sub>(recessive)</sub>
GG/-	1,088	11.1	0.26 to 21.94	0.045	
GG/GG	113	37.77	3.24 to 72.3	0.032	
<i>CCND1</i> haplotype 2 (rs667515, rs9344) <sup>e</sup>					
-/-	1,251	20.66	10.07 to 31.24	< 0.001	0.022 <sub>(codominant)</sub>
GA/-	2,150	13.75	5.34 to 22.15	0.001	
GA/GA	925	6.08	-4.5 to 16.67	0.26	
<i>CCND1</i> haplotype 3 (rs667515, rs9344) <sup>e</sup>					
-/-	1,678	10.28	1.22 to 19.35	0.026	0.003 <sub>(recessive)</sub>
CG/-	2,048	11.92	3.4 to 20.44	0.006	
CG/CG	600	30.9	17.21 to 44.58	< 0.001	
<i>CCND1</i> haplotype 4 (rs667515, rs9344) <sup>e</sup>					
-/-	4,239	13.52	6.22 to 20.82	< 0.001	0.434 <sub>(codominant)</sub>
CA/-	84	-1.4	-39.67 to 36.88	0.943	
CA/CA	3	-11.8	-468.22 to 444.62	0.96	

<sup>a</sup>Covariates were age, sex, height, parental smoking, sine and cosine function of day of examination to control for seasonal effects, level of education at SAPALDIA1, change in level of education, Swiss nationality, self-reported occupational exposure to dust and occupational exposure to fumes at SAPALDIA1 and SAPALDIA2 (yes/no), smoking status at SAPALDIA2 (never, former, or current), pack-years up to SAPALDIA1, pack-years between SAPALDIA1 and -2, cigarettes per day at SAPALDIA1 and -2, atopy, BMI at SAPALDIA1, change in BMI, interaction between the two BMI variables, and baseline PM<sub>10</sub> exposure. <sup>b</sup>Positive estimates indicate attenuation of lung function decline associated with PM<sub>10</sub> decrease. Negative estimates indicate acceleration of lung function decline with PM<sub>10</sub> decrease. <sup>c</sup>p-Value for interaction between change in home outdoor exposure of PM<sub>10</sub> and genotype parameterized in three different genetic models. The p<sub>int</sub> values presented here represent the most significant (lowest) p-value obtained from the three different genetic models. Bonferroni significance level for 12 comparisons [three respiratory function tests (FVC, FEV<sub>1</sub>, FEF<sub>25-75</sub>) × times four association tests],  $p = 0.00417$ . <sup>d</sup>Genotype distribution: p21 CA,  $n = 594$ ; p21 AA,  $n = 31$ . <sup>e</sup>Diplotype distribution is labeled as follows: -/-, none of the specific haplotype present; (rs667515, rs9344)/- (e.g., GG/-), one of the specific haplotypes present; (rs667515, rs9344)/(rs667515, rs9344) (e.g., GG/GG), for two of the specific haplotypes present.

## Discussion

Understanding the pathways by which PM<sub>10</sub> damages lung structures and identifying susceptible subjects are important steps in managing the public health challenges of anthropogenic ambient air pollution. In this study, we present novel evidence that genetic polymorphisms in the cell fate controlling genes, *p53*, *p21*, and *CCND1* may modify the degree to which adults benefit from improved air quality. If confirmed by independent studies, the results are of public health relevance. The observed difference between genotype subgroups with regard to ΔPM<sub>10</sub> effects on average lung function decline ranged between 11 mL/year and 21 mL/year for FEF<sub>25-75</sub>. This difference compares with the observed excess mean annual decline in FEF<sub>25-75</sub> of 18 mL and 14 mL per pack per day smoked during follow-up by, respectively, male and female SAPALDIA participants who smoked at baseline (modeled according to Downs et al. 2005). This difference in lung function decline may seem small in absolute terms and from an individual perspective, but even slight shifts in the population distribution of lung function can substantially increase the prevalence of subjects exhibiting respiratory function below clinical thresholds. In addition, lung function is known to be a strong and independent predictor of overall mortality (Künzli et al. 2000a, 2000b).

The mechanisms by which air pollutants induce harmful changes in bronchial tissue and ultimately lead to respiratory symptoms and clinically relevant respiratory dysfunction have been investigated. It seems well established that PM directly increases oxidative stress (Donaldson et al. 2003), activates the expression of proinflammatory cytokines (e.g., tumor necrosis factor α, nuclear factor-κβ, and interleukin-8) (Rahman et al. 2002) and induces the homing of inflammatory cells such as neutrophils, alveolar macrophages, and dendritic cells, thus resulting in inflammation of the lung (Behndig et al. 2006; Bosson et al. 2008; Li et al. 1996, 1997; Nightingale et al. 2000). The toxic effects of PM are further enhanced by bronchial tissue injuries and increased epithelial permeability (Morrison et al. 1999).

Our results are in line with more recent *in vitro* experiments with different types of bronchial cell lines demonstrating that PM induces cell proliferation arrest and apoptosis in exposed cells (Bayram et al. 2006; Dagher et al. 2006; Rosas Perez et al. 2007; Soberanes et al. 2006; Upadhyay et al. 2003; Zhang et al. 2007). Air pollutants or cigarette smoke, both exhibiting oxidative properties, specifically alter the expression levels of tumor suppressor genes such as *p53* and *p21* and of the cell cycle control gene *CCND1* in human and rodent *in vitro* bronchial cell culture

models. Although *p53* and *p21* expression has been consistently shown to be increased upon PM exposure (Bayram et al. 2006; Dagher et al. 2006; Jiao et al. 2008; Nyunoya et al. 2006; Palozza et al. 2006; Rosas Perez et al. 2007; Soberanes et al. 2006; Yao et al. 2008; Zhang et al. 2007), *CCND1* expression has been reported to be either inhibited (via *p21* activation) (Palozza et al. 2006; Zhang et al. 2007) or increased [*p53*-driven N-terminal C-Jun kinase (*cJUN*) activation] (Bayram et al. 2006; Dagher et al. 2007; Jiao et al. 2008). Such variations in the expression of cell cycle genes mediate the adaptive cellular response to changes in environmental exposure. They might well be the starting point of PM<sub>10</sub>-induced pathologic changes in morphology and in the type and number of lung fibroblasts and bronchial epithelial cells. Activation of cell proliferation processes may help to maintain intact airways even in the presence of environmental toxins, as suggested by genetic ablation of *p21* in mice, which conferred protection against cigarette-smoke-induced lung inflammation and injury (Yao et al. 2008). Aspects of bronchial tissue remodeling represent key features of pathologic changes in the etiology of most airway disorders. However, how proliferation and apoptosis relate to airway remodeling in general remains poorly understood and is likely to be disease specific.

Three of the four polymorphisms investigated here have been studied before, mainly in cancer studies, and allelic functional differences have been proposed. The functional consequence of *p53* R72P polymorphism was studied in detail. The Arg72-allele (G-allele) of *p53* is more active at inducing apoptosis than is the *p53* Pro72-allele. In fact, Pro72 is part of a PXXP motif known to be critical in binding of a *p53*-specific inhibitory protein, iASPP (inhibitory member of the apoptosis-stimulating protein phosphatase family) (Bergamaschi et al. 2006). Along the line of the proposed functional consequence of this genetic variant, meta-analysis results have recently shown that the homozygous Pro/Pro genotype showed a proproliferative effect and was associated with increased gastric cancer risk (Zhou et al. 2007). In our association study, we observed the most pronounced benefits of ΔPM<sub>10</sub> with regard to FEF<sub>25-75</sub> decline in subjects with one or two Arg72-alleles, which are expected to induce apoptosis more potently than the Pro72-allele. In contrast, homozygous carriers of the Pro72-allele did not appear to benefit from the improvement in air quality.

The functional studies of the common *CCND1* polymorphism P242P showed a modification of the alternative splicing events in exon 4 because the G-to-A substitution alters the consensus sequence of the splicing

donor site (Betticher et al. 1995; Howe and Lynas 2001). As recently reported by three meta-analyses, the homozygous AA genotype was associated with increased risk of various types of cancer (Lu et al. 2008; Pabalan et al. 2008; Tan et al. 2008). The A-allele of the *CCND1* 870G>A (P242P) polymorphism, a proposed genetic risk factor for lung cancer, was previously associated with impaired cell cycle regulation and accumulation of DNA damage in the airway (Buch et al. 2005; Munnia et al. 2006). In our association analysis, we observed that homo- or heterozygous G-allele carriers benefited more from the decrease in PM<sub>10</sub> exposure than did homozygous A-allele carriers. The association of the second *CCND1* (-7006G>C) SNP with cancer or any other outcome has not been investigated previously. Its functional consequence, if any, might be regulatory because it is situated upstream of the *CCND1* gene. But it is also possible that this SNP is in high linkage with a yet unknown functional *CCND1* variant, just as it is also in high LD with the *CCND1* P242P variant.

The polymorphism S31R in the *p21* gene was shown to be located in the DNA-binding zinc finger motif and thus has been thought to alter the function of the *p21* protein (Lukas et al. 1997). However, results of cancer studies for this SNP have been inconsistent with regard to the size and direction of relative risk estimates (Choi et al. 2008), and we observed no interaction between this SNP and ΔPM<sub>10</sub> on lung function decline.

Thus, the cancer-promoting *p53* and *CCND1* alleles seem to reduce the benefit of improved air quality on respiratory function. Only limited epidemiological data exist on the association of *p53*, *p21*, or *CCND1* SNPs with respiratory diseases such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD). The polymorphisms we evaluated in *p53* and *p21* have previously been associated with smoking-related COPD. Compared with healthy smokers, the cancer risk allele of *p53* (Pro72-allele), and the *p21* Arg31-allele were overrepresented in COPD patients (Lee et al. 2006). The extrapolation of observed associations with cancer to expected associations with lung function is not straightforward. The present findings and our interpretation of them should be considered as exploratory in nature and need confirmation in independent studies. The relative impacts of cell proliferation and apoptosis on different cell types in the lung and on respiratory function must be further investigated by experimental studies.

The strengths of the present study are its prospective design, its rather large sample size, and detailed characterization of the study participants, as well as the availability of individual air pollution exposure history

since 1990. We were thus able to adjust lung function decline for most of the potential confounders. Nonetheless, information on some relevant confounders such as dietary antioxidant intake and physical activity was collected only at follow-up. Lacking data on the degree of genetic admixture of the Swiss general population is an additional drawback. However, we expect little bias due to genetic admixture, because the prevalence of several polymorphisms studied in the cohort did not vary across the three major Swiss language groups. We assessed a very limited number of carefully selected candidate polymorphisms; for some of the SNPs and haplotypes, and especially for the

#### Appendix 1. The SAPALDIA Team.

Member	Specialty
<b>Study directorate</b>	
U. Ackermann-Liebrich	Epidemiology
J.M. Gaspoz	Cardiology
P. Leuenberger	Pneumology
L.J.S. Liu	Exposure
N.M. Probst Hensch	Epidemiology/genetic and molecular biology
C. Schindler	Statistics
T. Rochat	Pneumology
<b>Scientific team</b>	
J.C. Barthélémy	Cardiology
W. Berger	Genetic and molecular biology
R. Bettschart	Pneumology
A. Bircher	Allergology
G. Bolognini	Pneumology
O. Brändli	Pneumology
M. Brutsche	Pneumology
L. Burdet	Pneumology
M. Frey	Pneumology
M.W. Gerbase	Pneumology
D. Gold	Epidemiology/cardiology/pneumology
W. Karrer	Pneumology
R. Keller	Pneumology
B. Knöpfli	Pneumology
N. Künzli	Epidemiology/exposure
U. Neu	Exposure
L. Nicod	Pneumology
M. Pons	Pneumology
E. Russi	Pneumology
P. Schmid-Grendelmeyer	Allergology
J. Schwartz	Epidemiology
P. Straehl	Exposure
J.M. Tschoop	Pneumology
A. von Eckardstein	Clinical chemistry
J.P. Zellweger	Pneumology
E. Zemp Stutz	Epidemiology
<b>Scientific team at coordinating centers</b>	
P.O. Bridevaux	Pneumology
I. Curjuric	Epidemiology
J. Dratva	Epidemiology
D. Felber Dietrich	Cardiology
D. Keidel	Statistics
M. Imboden	Genetic and molecular biology
H. Phuleria	Exposure
E. Schaffner	Statistics
G.A. Thun	Genetic and molecular biology



*p21* SNP and *CCND1* haplotype 4, statistical power to detect effect estimation was very limited. A more comprehensive assessment of gene variants in the apoptosis pathway and genes regulating apoptosis in lung tissue needs to be addressed in future larger studies. Nevertheless, even for the small number of genetic variants investigated, multiple testing represents a limitation in the interpretation of the present results. Consistency of the associations across genes involved in cell cycle control, as well as across various lung function outcomes, diminishes the likelihood of chance findings, as does the strength of the observed  $p_{int}$  values.

Finally, participation at follow-up and in this present study was not complete, so participation bias cannot be excluded. However, because we observed comparable results in all subjects and in never-smokers and in the absence of different effects between men and women, the lower participation rate in men and smokers is not likely to have caused bias.

In conclusion, our results suggest that even at low to moderate levels of air pollution, such as in Switzerland, some but not all persons benefit from improved air quality. Given the novelty of the finding and the limitations inherent to this study, the results need independent confirmation. Future studies must address additional issues. First, gene variants relevant to cell cycle control must be studied more comprehensively. Second, it is of interest to know whether this novel candidate pathway might determine susceptibility to both improvements and declines in air quality.

## REFERENCES

- Ackermann-Lieblich U, Kuna-Dibbert B, Probst-Hensch N, Schindler C, Felber Dietrich D, Zemp Stutz E, et al. 2005. Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991–2003: methods and characterization of participants. *Soz Präventiv Med* 50:245–263.
- Ackermann-Lieblich U, Leuenberger P, Schwartz J, Schindler C, Monn C, Bolognini G, et al. 1997. Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. *Am J Respir Crit Care Med* 155(1):122–129.
- American Thoracic Society. 1995. Standardization of spirometry, 1994 Update. *Am J Respir Crit Care Med* 152(3):1107–1136.
- Bayram H, Ito K, Issa R, Ito M, Sukkar M, Chung KF. 2006. Regulation of human lung epithelial cell numbers by diesel exhaust particles. *Eur Respir J* 27(4):705–713.
- Behndig AF, Mudway IS, Brown JL, Stenforns N, Helleday R, Duggan ST, et al. 2006. Airway antioxidant and inflammatory responses to diesel exhaust exposure in healthy humans. *Eur Respir J* 27(2):359–365.
- Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breysens H, Bisso A, et al. 2006. iASP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. *Nat Genet* 38(10):1133–1141.
- Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. 1995. Alternate splicing produces a novel cyclin D1 transcript. *Oncogene* 11(5):1005–1011.
- Bosson J, Barath S, Pourazar J, Behndig AF, Sandstrom T, Blomberg A, et al. 2008. Diesel exhaust exposure enhances the ozone induced airway inflammation in healthy humans. *Eur Respir J* 31(6):1234–1240.
- Brunekef B, Forsberg B. 2005. Epidemiological evidence of effects of coarse airborne particles on health. *Eur Respir J* 26(2):309–318.
- Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR, et al. 2005. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. *Mol Carcinog* 42(4):222–228.
- Burney PG, Luczynska C, Chinn S, Jarvis D. 1994. The European Community Respiratory Health Survey. *Eur Respir J* 7(5):954–960.
- Burr ML, Karani G, Davies B, Holmes BA, Williams KL. 2004. Effects on respiratory health of a reduction in air pollution from vehicle exhaust emissions. *Occup Environ Med* 61(3):212–218.
- Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. 2005. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. *Carcinogenesis* 26(8):1457–1464.
- Choi YY, Kang HK, Choi JE, Jang JS, Kim EJ, Cha SI, et al. 2008. Comprehensive assessment of P21 polymorphisms and lung cancer risk. *J Hum Genet* 53(1):87–95.
- Dagher Z, Garcon G, Billet S, Gosset P, Ledoux F, Courcot D, et al. 2006. Activation of different pathways of apoptosis by air pollution particulate matter (PM2.5) in human epithelial lung cells (L132) in culture. *Toxicology* 225(1):12–24.
- Dagher Z, Garcon G, Billet S, Verdin A, Ledoux F, Courcot D, et al. 2007. Role of nuclear factor-kappa B activation in the adverse effects induced by air pollution particulate matter (PM2.5) in human epithelial lung cells (L132) in culture. *J Appl Toxicol* 27(3):284–290.
- Donaldson K, Stone V, Borm PJ, Jimenez LA, Gilmour PS, Schins RP, et al. 2003. Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). *Free Radic Biol Med* 34(11):1369–1382.
- Downs S, Brandli O, Zellweger JP, Schindler C, Künzli N, Gerbase M, et al. 2005. Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study. *Respir Res* 6(1):45; doi:10.1186/1465-9921-6-45 [Online 26 May 2005].
- Downs SH, Schindler C, Liu LJ, Keidel D, Bayer-Oglesby L, Brutsche MH, et al. 2007. Reduced exposure to PM10 and attenuated age-related decline in lung function. *N Engl J Med* 357(23):2338–2347.
- Goodman P, Agnew M, McCaffrey M, Paul G, Clancy L. 2007. Effects of the Irish smoking ban on respiratory health of bar workers and air quality in Dublin pubs. *Am J Respir Crit Care Med* 175(8):840–845.
- Gotschi T, Heinrich J, Sunyer J, Künzli N. 2008. Long-term effects of ambient air pollution on lung function: a review. *Epidemiology* 19(5):690–701.
- Hedley AJ, Wong CM, Thach TQ, Ma S, Lam TH, Anderson HR. 2002. Cardiorespiratory and all-cause mortality after restrictions on sulphur content of fuel in Hong Kong: an intervention study. *Lancet* 360(9346):1646–1652.
- Howe D, Lynas C. 2001. The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. *Haematologica* 86(6):563–569.
- Imboden M, Downs SH, Senn O, Matyas G, Brandli O, Russi EW, et al. 2007. Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study. *Respir Res* 8:2; doi:10.1186/1465-9921-8-2 [Online 11 January 2007].
- Jiao S, Liu B, Gao A, Ye M, Jia X, Zhang F, et al. 2008. Benzo(a)pyrene-caused increased G(1)-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblasts. *Toxicol Lett* 178(3):167–175.
- Künzli N, Ackermann-Lieblich U, Brandli O, Tschopp JM, Schindler C, Leuenberger P. 2000a. Clinically “small” effects of air pollution on FVC have a large public health impact. *Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA) team. Eur Respir J* 15(1):131–136.
- Künzli N, Ackermann-Lieblich U, Keller R, Perruchoud AP, Schindler C. 1995. Variability of FVC and FEV1 due to technician, team, device and subject in an eight centre study: three quality control studies in SAPALDIA. *Swiss Study on Air Pollution and Lung Disease in Adults. Eur Respir J* 8(3):371–376.
- Künzli N, Kaiser R, Medina S, Studnicka M, Chanel O, Filiger P, et al. 2000b. Public-health impact of outdoor and traffic-related air pollution: a European assessment. *Lancet* 356(9232):795–801.
- Künzli N, Kuna-Dibbert B, Keidel D, Keller R, Brändli O, Schindler C, et al. 2005. Longitudinal validity of spirometers—a challenge in lung function follow-up studies. *Swiss Med Wkly* 135(33–34):503–508.
- Lee YL, Chen W, Tsai WK, Lee JC, Chiou HL, Shih CM, et al. 2006. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. *J Lab Clin Med* 147(5):228–233.
- Li N, Xia T, Nel AE. 2008. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. *Free Radic Biol Med* 44(9):1689–1699.
- Li XY, Gilmour PS, Donaldson K, MacNee W. 1996. Free radical activity and pro-inflammatory effects of particulate air pollution (PM<sub>10</sub>) in vivo and in vitro. *Thorax* 51(12):1216–1222.
- Li XY, Gilmour PS, Donaldson K, MacNee W. 1997. *In vivo* and *in vitro* proinflammatory effects of particulate air pollution (PM<sub>10</sub>). *Environ Health Perspect* 105(suppl 5):1279–1283.
- Liu LJ, Curjuric I, Keidel D, Heldstab J, Künzli N, Bayer-Oglesby L, et al. 2007. Characterization of source-specific air pollution exposure for a large population-based Swiss cohort (SAPALDIA). *Environ Health Perspect* 115:1638–1645.
- Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, et al. 2008. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. *Breast Cancer Res Treat* 116(3):571–575.
- Lukas J, Groshen S, Saffari B, Niu N, Reles A, Wen WH, et al. 1997. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. *Am J Pathol* 150(1):167–175.
- Martin BV, Ackermann-Lieblich U, Leuenberger P, Künzli N, Stutz EZ, Keller R, et al. 1997. SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. *Soz Präventivmed* 42(2):67–84.
- Menzies D, Nair A, Williamson PA, Schembri S, Al-Khairalla MZ, Barnes M, et al. 2006. Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places. *JAMA* 296(14):1742–1748.
- Morrison D, Rahman I, Lannan S, MacNee W. 1999. Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. *Am J Respir Crit Care Med* 159(2):473–479.
- Munnia A, Bonassi S, Verna A, Quaglia R, Pelucco D, Ceppi M, et al. 2006. Bronchial malondialdehyde DNA adducts, tobacco smoking, and lung cancer. *Free Radic Biol Med* 41(9):1499–1505.
- Nightingale JA, Maggs R, Cullinan P, Donnelly LE, Rogers DF, Kinnerley R, et al. 2000. Airway inflammation after controlled exposure to diesel exhaust particulates. *Am J Respir Crit Care Med* 162(1):161–166.
- Nyunoya T, Monick MM, Klingelutz A, Yarovinsky TO, Cagle JR, Hunninghake GW. 2006. Cigarette smoke induces cellular senescence. *Am J Respir Cell Mol Biol* 35(6):681–688.
- Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, et al. 2002. Regulation of p53: intricate loops and delicate balances. *Biochem Pharmacol* 64(5–6):865–871.
- Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H. 2008. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 17(10):2773–2781.
- Palozza P, Serini S, Curro D, Calviello G, Igarashi K, Mancuso C. 2006. beta-Carotene and cigarette smoke condensate regulate heme oxygenase-1 and its repressor factor Bach1: relationship with cell growth. *Antioxid Redox Signal* 8(5–6):1069–1080.
- Probst-Hensch NM, Sun CL, Van Den Berg D, Ceschi M, Koh WP, Yu MC. 2006. The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study. *Carcinogenesis* 27(12):2475–2482.
- Rahman I, Gilmour PS, Jimenez LA, MacNee W. 2002. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. *Mol Cell Biochem* 234–235(1–2):239–248.
- Ranjan P, Anathy V, Burch PM, Weirather K, Lambeth JD, Heintz NH. 2006. Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. *Antioxid Redox Signal* 8(9–10):1447–1459.
- Rosas Perez I, Serrano J, Alfaro-Moreno E, Baumgardner D, Garcia-Cuellar C, Martin Del Campo JM, et al. 2007. Relations between PM10 composition and cell toxicity:

- a multivariate and graphical approach. *Chemosphere* 67(6):1218–1228.
- Soberanes S, Panduri V, Mutlu GM, Ghio A, Bundinger GR, Kamp DW. 2006. p53 mediates particulate matter-induced alveolar epithelial cell mitochondria-regulated apoptosis. *Am J Respir Crit Care Med* 174(11):1229–1238.
- Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 68(4):978–989.
- Tan XL, Nieters A, Kropp S, Hoffmeister M, Brenner H, Chang-Claude J. 2008. The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. *Int J Cancer* 122(11):2573–2580.
- Upadhyay D, Panduri V, Ghio A, Kamp DW. 2003. Particulate matter induces alveolar epithelial cell DNA damage and apoptosis: role of free radicals and the mitochondria. *Am J Respir Cell Mol Biol* 29(2):180–187.
- Wutrich B, Schindler C, Medici TC, Zellweger JP, Leuenberger P. 1996. IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team. *Int Arch Allergy Immunol* 111(4):396–402.
- Yao H, Edirisinghe I, Yang SR, Rajendrasozhan S, Kode A, Caito S, et al. 2008. Genetic ablation of NADPH oxidase enhances susceptibility to cigarette smoke-induced lung inflammation and emphysema in mice. *Am J Pathol* 172(5):1222–1237.
- Zhang J, Ghio AJ, Gao M, Wei K, Rosen GD, Upadhyay D. 2007. Ambient particulate matter induces alveolar epithelial cell cycle arrest: role of G1 cyclins. *FEBS Lett* 581(27):5315–5320.
- Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. 2007. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. *Int J Cancer* 121(7):1481–1486.